Trials / Completed
CompletedNCT04225260
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
A Multicenter, Open-Label Study to Evaluate the Safety of QM1114-DP for the Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 902 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | botulinum toxin neuromodulator | A dose of QM1114-DP will be injected in the GL area and in the LCL area. |
Timeline
- Start date
- 2020-01-27
- Primary completion
- 2021-04-12
- Completion
- 2021-05-21
- First posted
- 2020-01-13
- Last updated
- 2023-06-18
- Results posted
- 2023-06-18
Locations
30 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04225260. Inclusion in this directory is not an endorsement.